No Data
No Data
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $61
Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept's Potential in IgA Nephropathy
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?